G. L.-H. Wong, H. L.-Y. Chan, K. K.-L. Yiu, J. W.-Y. Lai, V. K.-K. Chan, K. K.-C. Cheung, etal. Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma:517–526
S. L. Szeinbach, R. W. Baran, B. Dietz, L. Gazzouola Rocca, D. Littlefield and B. P. Yawn. Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument:573–582
J. H. Tabibian, E. Weeding, R. A. Jorgensen, J. L. Petz, J. C. Keach, J. A. Talwalkar, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis – a pilot study:604–612
Y. S. de Boer, N. M. F. van Gerven, N. K. H. de Boer, C. J. J. Mulder, G. Bouma and C. M. J. van Nieuwkerk.Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis:640–646
Z. M. Younossi, M. Stepanova, F. Nader, Z. Younossi and E. Elsheikh. Associations of chronic hepatitis C with metabolic and cardiac outcomes:647–652
